Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.
Van der Kolk WL, Van der Zee AGJ, Slomovitz BM, Baldwin PJW, Van Doorn HC, De Hullu JA, Van der Velden J, Gaarenstroom KN, Slangen BFM, Kjolhede P, Brännström M, Vergote I, Holland CM, Coleman R, Van Dorst EBL, Van Driel WJ, Nunns D, Widschwendter M, Nugent D, DiSilvestro PA, Mannel RS, Tjiong MY, Boll D, Cibula D, Covens A, Provencher D, Runnebaum IB, Monk BJ, Zanagnolo V, Tamussino K, Oonk MHM; all GROINSS-V I and II participants. Van der Kolk WL, et al. Among authors: van dorst ebl, van doorn hc, van der velden j, van driel wj, van der zee agj. Gynecol Oncol. 2022 Oct;167(1):3-10. doi: 10.1016/j.ygyno.2022.07.017. Epub 2022 Sep 7. Gynecol Oncol. 2022. PMID: 36085090 Free article.
What is the role of dose-dense therapy?
van der Burg ME, van der Gaast A, Vergote I, Burger CW, van Doorn HC, de Wit R, Stoter G, Verweij J. van der Burg ME, et al. Among authors: van doorn hc, van der gaast a. Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:233-40. doi: 10.1111/j.1525-1438.2005.00432.x. Int J Gynecol Cancer. 2005. PMID: 16343238 Free article. Review.
Management of recurrent endometrioid endometrial carcinoma: an overview.
van Wijk FH, van der Burg ME, Burger CW, Vergote I, van Doorn HC. van Wijk FH, et al. Among authors: van doorn hc, van der burg me. Int J Gynecol Cancer. 2009 Apr;19(3):314-20. doi: 10.1111/IGC.0b013e3181a7f71e. Int J Gynecol Cancer. 2009. PMID: 19407552 Review.
Increased incidence and improved survival in endometrioid endometrial cancer diagnosed since 1989 in The Netherlands: a population based study.
Boll D, Karim-Kos HE, Verhoeven RH, Burger CW, Coebergh JW, van de Poll-Franse LV, van Doorn HC. Boll D, et al. Among authors: van doorn hc, van de poll franse lv. Eur J Obstet Gynecol Reprod Biol. 2013 Feb;166(2):209-14. doi: 10.1016/j.ejogrb.2012.10.028. Epub 2012 Nov 22. Eur J Obstet Gynecol Reprod Biol. 2013. PMID: 23176760
Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
van der Burg ME, Vergote I, Onstenk W, Boere IA, Leunen K, van Montfort CA, van Doorn HC. van der Burg ME, et al. Among authors: van montfort ca, van doorn hc. Eur J Cancer. 2013 Apr;49(6):1254-63. doi: 10.1016/j.ejca.2012.11.027. Epub 2012 Dec 29. Eur J Cancer. 2013. PMID: 23276720 Clinical Trial.
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2; Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A; Australian Ovarian Cancer Study Group; Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H; Breast Cancer Family Register; Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brüning T, Budzilowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KBM, Collée JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks EM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Silva IDS, du Bois A, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards R… See abstract for full author list ➔ Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, et al. Among authors: van asperen cj, van nieuwenhuysen e, van t veer lj, van der baan fh, van rensburg ej, van den ouweland amw, van den berg d, van doorn hc, van altena am. Gynecol Oncol. 2016 May;141(2):386-401. doi: 10.1016/j.ygyno.2015.04.034. Epub 2015 May 2. Gynecol Oncol. 2016. PMID: 25940428 Free PMC article. Review.
120 results